ArticleBMC biotechnology2025
FOXD1, a hypoxia-related gene, accelerates prostate cancer cell growth by increasing glycolysis under hypoxia conditions.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia is a key feature of the tumor microenvironment, and can promote tumor progression. FOXD1 has been found to be involved in several types of cancer; however, its role in mediating cancer cell growth under hypoxia conditions is unclear. In this study, we aimed to test the effect of FOXD1 on prostate cancer cell growth in response to hypoxia. Our results showed that FOXD1 expression was upregulated in prostate cancer. Under normoxia conditions, FOXD1 knockdown inhibited prostate cancer cell viability and colony formation, while FOXD1 overexpression exhibited the opposite effects. Hypoxia exposure increased the expression of FOXD1 in prostate cancer. FOXD1 knockdown inhibited hypoxia-induced increase in cell viability and colony formation ability, whereas FOXD1 overexpression showed the opposite effects. In addition, FOXD1 knockdown inhibited hypoxia-induced increase in lactate production, glucose consumption, and the expression levels of HK-2 and LDHA. Moreover, inhibition of glycolysis by 2-deoxyglucose reversed the effect of FOXD1 overexpression on hypoxia-induced prostate cancer cell growth. These results indicated that hypoxia-induced FOXD1 expression accelerated glycolysis, ultimately promoting prostate cancer cell growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.